Critics of the "most favored nation" concept argue that drug companies could game the system by securing deals with foreign governments for rebates to maintain current drug pricing in the U.S.

President Donald Trump on Monday delivered a blow to the private-sector middlemen who negotiate U.S. drug prices in his executive order on drug pricing, saying he would cut them out as part of a goal ...

Rather than cutting prices there, many firms would raise them abroad and perhaps pull out of some countries altogether, meaning Mr Trump’s policy would shrink their businesses while doing little to lo...